Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
Rhea-AI Summary
Moderna (NASDAQ:MRNA) will hold a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results and provide a corporate update.
The live and archived webcasts will be available in the Investors section of Moderna's website.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings date: MRNA +3.74% in the Jul 9 session
In the Jul 9 session, MRNA gained 3.74%, reflecting a moderate positive market reaction. Argus tracked a trough of -12.3% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Earnings date notice | Neutral | +2.7% | Scheduled release of first quarter 2026 results with 8:00 a.m. ET call. |
| Jan 26 | Earnings date notice | Neutral | -1.5% | Announced date and time for fourth quarter 2025 earnings call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date notices produced only modest share moves around the scheduling announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire